SGS certifies Valtris Speciality Chemical site as GMP

Published: 26-Feb-2019 Featured companies: SGS Health Sciences
Regulatory

Certification body of EXCiPACT, SGS, has certified that the Cleveland site manufactures metal stearate to GMP standard

Valtris Specialty Chemical’s Cleveland, Ohio site has been awarded an EXCiPACT GMP Certificate. The Certificate demonstrates that this site manufactures metal stearates as pharmaceutical excipients according to the ExciPact GMP Certification Standard.

For details of SGS' assessment process and other EXCiPACT certified sites click here

Featured companies

SGS’s global network of analytical testing, formulation, clinical research, and clinical manufacturing solutions offer a wide range of integrated services and expertise...
  • Companies:
  • EXCiPACT
See more

You may also like

Regulatory

SGS Laboratory's Fairfield site achieves ISO/IEC 17025:2017 certification

Read more
The world’s leading testing, inspection and certification company has announced that its Fairfield laboratory has earned its ISO/IEC 17025:2017 certification

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  3. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  4. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  5. Innovating with purpose for safety and security of outcome Beyond the importance of increasing productivity and generating more output and value with the same input, new ideas and technologies from GEA take innovation a step further

Relevant companies

See more

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Regulatory

SGS Laboratory's Fairfield site achieves ISO/IEC 17025:2017 certification

The world’s leading testing, inspection and certification company has announced that its Fairfield laboratory has earned its ISO/IEC 17025:2017 certification
Manufacturing

SGS recognised as business leader at Scotland’s Life Sciences Awards 2023

In December, SGS committed to increasing its biosafety testing capacity, with a £10 million investment, to support the roll-out of the COVID-19 vaccines throughout 2021 and 2022
Regulatory

Nitrosamine testing: the regulatory aspects

Subsequent to the detection of nitrosamines in pharmaceuticals in 2018, this class of impurities has been a pressing topic in the pharmaceutical world. The US FDA, EMA and other regulatory agencies have issued new regulations and instructed all pharmaceutical manufacturers to conduct a risk assessment and proactively test their products for the presence of nitrosamines
Regulatory

ECCRT to provide GMP training for SGS pharmacy team

CCRT will provide training and educational materials across multiple domains, including good practices, quality assurance and risk management
Regulatory

Illinois Corn Processing site receives EXCiPACT certification

The certificate demonstrates the site manufactures ethyl alcohol intended for use as a pharmaceutical excipient according to the 2017 EXCiPACT GMP certification standard
Regulatory

JRS Pharma and Gujurat Microwax achieve EXCiPACT certification

EXCiPACT has certified sites in 21 countries to date including the UK, US, Japan and China
Regulatory

SGS enrols first patient into Biophytis COVA clinical study

The trial will examine a drug candidate for COVID-19 related acute respiratory failure treatment
Subscribe now